Form 4: Galectin Therapeutics Director Acquires Shares in Recent Transaction

Director Harold H. Shlevin of Galectin Therapeutics acquired 6,500 shares of common stock at a price of $1.16 per share on December 30, 2024.

Summary

• Harold H. Shlevin, a director at Galectin Therapeutics, purchased 6,500 shares of the company's common stock.
• The transaction occurred on December 30, 2024.
• The purchase price was $1.16 per share.
• Following the transaction, Mr. Shlevin directly owns 15,206 shares of Galectin Therapeutics common stock.

Sentiment

Score: 6

Explanation: The document is a routine filing of an insider transaction. It is neither particularly positive nor negative, but the purchase of shares by a director is generally viewed as a neutral to slightly positive signal.

Positives

• The purchase of shares by a director could be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It provides transparency into insider trading activity.

Comparison to Industry Standards

• Form 4 filings are a standard practice for all publicly traded companies in the US, ensuring transparency of insider transactions.
• The transaction is relatively small in terms of volume, and is not unusual for a director of a company.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment due to the director's purchase.

Key Dates

Keywords

Galectin Therapeutics, GALT, insider trading, share purchase, director, Harold H. Shlevin, common stock